Agilon Health (NYSE:AGL) Rating Lowered to Underweight at JPMorgan Chase & Co.

Key Points

• JPMorgan downgraded Agilon Health (NYSE:AGL) from "neutral" to "underweight" with a $21 price target, implying about a 29% downside from the stock's current level.
• Analyst views are mixed: the MarketBeat consensus is a "Hold" with a $38.48 average target, while individual firms range from "sell"/"underweight" to "overweight."
• Recent fundamentals show a quarterly EPS miss (reported ($0.46) vs. ($0.27) expected) despite revenue of $1.57B, with negative ROE and net margin; the company has a market cap of roughly $493M and a 52-week range of $7.48–$119.50.

Agilon Health (NYSE:AGL - Get Free Report) was downgraded by stock analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating in a research report issued to clients and investors on Monday. They currently have a $21.00 target price on the stock. JPMorgan Chase & Co.'s price target would indicate a potential downside of 29.01% from the company's current price.

Several other research firms have also recently issued reports on AGL. Deutsche Bank Aktiengesellschaft set a $33.00 target price on Agilon Health and gave the stock a "hold" rating in a research report on Thursday, April 9th. Citigroup cut their target price on Agilon Health from $21.25 to $18.75 and set a "neutral" rating for the company in a research report on Tuesday, March 3rd. Barclays cut their target price on Agilon Health from $25.00 to $12.50 and set an "underweight" rating for the company in a research report on Friday, February 27th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Agilon Health in a research report on Monday, April 20th. Finally, Wells Fargo & Company increased their target price on Agilon Health from $25.00 to $37.50 and gave the stock an "overweight" rating in a research report on Friday, February 27th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Agilon Health presently has a consensus rating of "Hold" and a consensus target price of $38.48.

Agilon Health Stock Up 0.0%

NYSE AGL opened at $29.58 on Monday. The stock's 50-day moving average price is $17.16 and its 200-day moving average price is $17.96. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. Agilon Health has a 52 week low of $7.48 and a 52 week high of $119.50. The company has a market capitalization of $492.84 million, a P/E ratio of -1.25 and a beta of 2.29.

Agilon Health (NYSE:AGL - Get Free Report) last released its earnings results on Wednesday, February 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.19). Agilon Health had a negative return on equity of 120.82% and a negative net margin of 6.60%.The business had revenue of $1.57 billion for the quarter, compared to analysts' expectations of $1.46 billion. On average, equities research analysts predict that Agilon Health will post -6.35 earnings per share for the current year.

Hedge Funds Weigh In On Agilon Health

Institutional investors have recently added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC purchased a new position in Agilon Health during the 3rd quarter valued at approximately $26,000. LPL Financial LLC grew its holdings in Agilon Health by 213.4% during the 4th quarter. LPL Financial LLC now owns 44,055 shares of the company's stock valued at $30,000 after buying an additional 30,000 shares in the last quarter. Krilogy Financial LLC purchased a new position in Agilon Health during the 4th quarter valued at approximately $34,000. CIBC Bancorp USA Inc. purchased a new position in Agilon Health during the 3rd quarter valued at approximately $34,000. Finally, Merit Financial Group LLC purchased a new position in Agilon Health during the 4th quarter valued at approximately $35,000.

Agilon Health Company Profile

Agilon Health NYSE: AGL is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.